<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04748991</url>
  </required_header>
  <id_info>
    <org_study_id>REB20-2257</org_study_id>
    <nct_id>NCT04748991</nct_id>
  </id_info>
  <brief_title>Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients</brief_title>
  <official_title>Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-operative atrial fibrillation is a common problem post cardiac surgery with rates&#xD;
      exceeding 30%. Atrial fibrillation has multiple adverse effects on cardiac hemodynamics and&#xD;
      can lead to hypotension, diminished end organ perfusion and lengthen the stay in ICU.&#xD;
      Amiodarone is the medication of choice used for pharmacological cardioversion and can be used&#xD;
      with vasoactive medications. Intravenous amiodarone is associated with hypotension and end&#xD;
      organ perfusion requiring escalation in vasoactive support. Vernakalant is novel&#xD;
      anti-arrhythmic agent approved in Canada for cardioversion of atrial fibrillation that&#xD;
      primarily works on atrial channels and has no effect on contractility or vasodilation.&#xD;
      Clinical trials have proved good efficacy of Vernakalant in conversion of paroxysmal atrial&#xD;
      fibrillation however there is no comparison of Amiodarone to Vernakalant in post-operative&#xD;
      cardiac surgery. We plan to perform a clinical trial comparing Vernakalant to amiodarone in&#xD;
      post-cardiac surgery patients with a primary outcome of cardioversion at 90 minutes.&#xD;
      Secondary outcomes will follow duration of vasoactive medications, days in ICU and economics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Background - Atrial fibrillation (AF) is the most common cardiac arrhythmia post cardiac&#xD;
           surgery. Estimates suggest that rates of patients experiencing post-operative atrial&#xD;
           fibrillation (POAF) after cardiac surgery exceeds 30%. Atrial fibrillation has multiple&#xD;
           effects on the cardiopulmonary hemodynamics. Rapid irregular ventricular rate results in&#xD;
           decreased coronary flow diminishing the ability to preserve myocardial oxygen demand&#xD;
           leading to ischemia. Atrial contraction provides 15-20% of LV filling in normal cardiac&#xD;
           physiology and loss of synchronized atrial contraction in addition to decreased&#xD;
           diastolic filling time may lead to decreased cardiac. This may lead to hypotension and&#xD;
           diminished end organ perfusion requiring additional vasoactive support. Currently&#xD;
           amiodarone is utilized as the pharmacological agent of choice for POAF in cardiac&#xD;
           surgery, typical rate control agents are contraindicated due to need of vasoactive&#xD;
           requirements. However direct effects of IV amiodarone include vasodilation and&#xD;
           hypotension typically requiring escalating doses of vasoactive medications, which&#xD;
           subsequently prolong stay in the CVICU (cardiovascular Intensive Care Unit), increase&#xD;
           exposure to vasopressors and potentially mechanical ventilation. Vernakalant is a Von&#xD;
           Williams Class III novel anti-arrhythmic agent with primary activity on atrial tissue&#xD;
           with limited activity on ventricular myocardium. Primary mechanism of action is blocking&#xD;
           early activating K+ atrial channels and frequency-dependent atrial Na+ channels which&#xD;
           prolongs atrial refractory periods and decreasing atrial conduction without promoting&#xD;
           ventricular arrhythmia. There have been many trials that proven efficacy in converting&#xD;
           AF in patients with atrial fibrillation and in the post cardiac surgery patients,&#xD;
           however this has never been compared to standard of care Amiodarone.&#xD;
&#xD;
        2. Research Questions and objectives: We hypothesize administration of vernakalant compared&#xD;
           to amiodarone will have a higher rate of cardioversion to sinus rhythm at 90 min in&#xD;
           post-operative sustained atrial fibrillation. This will reduce duration of vasoactive&#xD;
           medications, days in ICU and mortality.&#xD;
&#xD;
        3. Methods: Patients will be recruited from the CVICU 24 hours after admission to CIVCU&#xD;
           based on inclusion and exclusion criteria. Patients identified with new presentation&#xD;
           atrial fibrillation with a sustained duration of greater than 30 minutes will be&#xD;
           considered for the study. Patients will be randomized to Amiodarone versus Vernakalant&#xD;
           using a computerized process. Patients randomized to an amiodarone arm will receive&#xD;
           150mg IV bolus and an amiodarone infusion of 1mg/hr x 6 hours followed by 0.5mg/hr x 12&#xD;
           hours. Patients randomized to Vernakalant will receive a bolus of 3mg/kg over 10 minutes&#xD;
           and an observation period of 15 minutes, if the patient is still in AF, they will&#xD;
           receive an additional 2.0mg/kg bolus of Vernakalant. Infusions will be discontinued if&#xD;
           QT interval becomes &gt;550ms, heart rate less than 45 bpm lasting &gt;30 seconds with&#xD;
           symptoms or &lt;40bpm lasting &gt;30 seconds with or without symptoms, ventricular tachycardia&#xD;
           or development of heart block. At 90 minutes rate of conversion to sinus rhythm will be&#xD;
           documented. Secondary outcomes including time to AF conversion, recurrence of atrial&#xD;
           fibrillation will be documented along with safety events over 48h. Duration of&#xD;
           vasoactive medications, days in ICU, time to initiation of beta blockers, mortality,&#xD;
           Left Ventricular (LV) function and economics of ICU still will be followed. Patients&#xD;
           will be excluded if they return to the OR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be recruited from the CVICU 24 hours after admission to CIVCU based on inclusion and exclusion criteria. Patients identified with new presentation atrial fibrillation with a sustained duration of greater than 30 minutes will be considered for the study. Patients will be randomized to Amiodarone versus Vernakalant using a computerized process.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of conversion of sustained post-operative atrial fibrillation at 90 minutes.</measure>
    <time_frame>90 minutes</time_frame>
    <description>Rate of conversion of sustained post-operative atrial fibrillation at 90 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of vasopressor therapy</measure>
    <time_frame>7 days</time_frame>
    <description>Duration of vasopressor therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to conversion to sinus rhythm</measure>
    <time_frame>7 days</time_frame>
    <description>Time to conversion to sinus rhythm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in intensive care unit</measure>
    <time_frame>7 Days</time_frame>
    <description>Days in intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of atrial fibrillation within 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Recurrence of atrial fibrillation within 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 month</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV function (Normal, Mild, Moderate or Severe)</measure>
    <time_frame>7 days</time_frame>
    <description>LV function (Normal, Mild, Moderate or Severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to initiation of beta-blockers</measure>
    <time_frame>7 days</time_frame>
    <description>Time to initiation of beta-blockers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economics - cost of hospital stay</measure>
    <time_frame>Up to one month</time_frame>
    <description>Economics - cost of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Post-cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Intravenous Vernakalant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to Vernakalant will receive a bolus of 3mg/kg over 10 minutes and an observation period of 15 minutes, if the patient is still in AF, they will receive an additional 2.0mg/kg bolus of Vernakalant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Amiodarone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to an amiodarone arm will receive 150mg IV bolus and an amiodarone infusion of 1mg/hr x 6 hours followed by 0.5mg/hr x 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vernakalant</intervention_name>
    <description>Post operative AF after cardiac surgery. Vernakalant 3mg/kg over 10 minutes followed by 2mg/kg over 10 minutes if still in AF.</description>
    <arm_group_label>Intravenous Vernakalant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Post operative AF after cardiac surgery. Amiodarone 150mg IV followed by 1 mg/min x 6 hours then 0.5 mg/min x 12 hours</description>
    <arm_group_label>Intravenous Amiodarone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;/=18 years&#xD;
&#xD;
          2. Undergone heart surgery for coronary artery bypass surgery (on-pump or off-pump CABG)&#xD;
             and/or valve repair or replacement (excluding mechanical valves), including&#xD;
             re-operations.&#xD;
&#xD;
          3. Hemodynamically stable with/without vasopressor support&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. LVAD insertion or heart transplantation&#xD;
&#xD;
          2. MAZE procedure&#xD;
&#xD;
          3. Transcatheter aortic valve replacement (TAVR)&#xD;
&#xD;
          4. History of or planned mechanical valve replacement&#xD;
&#xD;
          5. Rheumatic heart disease&#xD;
&#xD;
          6. Congenital cardiac defect (excluding bicuspid aortic valve or patent foramen ovale)&#xD;
&#xD;
          7. History of prior atrial fibrillation or flutter&#xD;
&#xD;
          8. History of ablation for atrial fibrillation&#xD;
&#xD;
          9. Contraindication to amiodarone&#xD;
&#xD;
               -  PR &gt;240ms&#xD;
&#xD;
               -  Heart block (2nd or 3rd degree)&#xD;
&#xD;
               -  QTC &gt;480ms&#xD;
&#xD;
               -  Untreated thyroid disorder&#xD;
&#xD;
               -  AST or ALT &gt;2x upper limit of normal&#xD;
&#xD;
               -  Hepatic cirrhosis&#xD;
&#xD;
               -  Interstitial lung disease&#xD;
&#xD;
         10. Received amiodarone within 6 weeks&#xD;
&#xD;
         11. Contraindications to Vernakalant&#xD;
&#xD;
               -  Known hypersensitivity to Vernakalant&#xD;
&#xD;
               -  Prolonged QT&#xD;
&#xD;
               -  Heart block (2nd or 3rd degree)&#xD;
&#xD;
               -  Use of anti-arrhythmic medication in the past 4 weeks.&#xD;
&#xD;
         12. Return to OR during CVICU stay or readmission to CIVCU from Cardiac Surgery ward.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Chiu, MD, MSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Chiu, MD, MSC</last_name>
    <phone>4032106818</phone>
    <email>michael.chiu@albertahealthservices.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vikas Kuriachan, MD</last_name>
    <phone>4032106818</phone>
    <email>vpkuriac@ucalgary.ca</email>
  </overall_contact_backup>
  <reference>
    <citation>Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 Mar 25;117(12):1518-25. doi: 10.1161/CIRCULATIONAHA.107.723866. Epub 2008 Mar 10.</citation>
    <PMID>18332267</PMID>
  </reference>
  <reference>
    <citation>Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009 Dec;2(6):652-9. doi: 10.1161/CIRCEP.109.870204.</citation>
    <PMID>19948506</PMID>
  </reference>
  <reference>
    <citation>Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G; AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011 Jan 18;57(3):313-21. doi: 10.1016/j.jacc.2010.07.046.</citation>
    <PMID>21232669</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amiodarone</keyword>
  <keyword>Vernakalant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Product monograph - Vernakalant</doc_type>
      <doc_url>https://pdf.hres.ca/dpd_pm/00038441.PDF</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Product monograph - Amiodarone</doc_type>
      <doc_url>https://pdf.hres.ca/dpd_pm/00035425.PDF</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

